BioCentury
ARTICLE | Company News

Management tracks: Rhythm, Redpin

October 15, 2018 11:48 PM UTC

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN). He replaces Fred Fideorek, who left Rhythm over the summer to join Intarcia Therapeutics Inc. (Boston, Mass.) as CMO and global head of regulatory affairs.

Neurology company Redpin Therapeutics Inc. (New York City, N.Y.) hired David Bleakman as CSO. Bleakman was VP, CSO and neuroscience site leader, New York, at Eli Lilly and Co. (NYSE:LLY). Founded in 2017, Redpin is developing chemogenetic therapies to targeted regulation of specific neuronal circuits in the brain to treat severe neurological disorders. The company’s founding investors include Arkin Bio Ventures, New York Ventures and Alexandria Venture Investments. ...